FDA is charged with the duty of regulating the manufacture, sale and distribution of both prescription drugs and nonprescription drugs (aka over-the-counter or OTC medications). A significant FDA role in the regulation of these medications is supporting sponsors in their efforts to ensure adequate drug product labeling. In this paper, we will describe the various types of drug “labeling” and their requirements. First, it is important to understand the regulatory distinction between “labels” and “labeling” which is illustrated as follows in Table 1:
[wpsm_comparison_table id=”14″ class=”customTable autoWidth twoRow textLeft VATop”]
FDA’s Guidance for Industry entitled “Help-Seeking” and Other Disease Awareness Communications by or on Behalf of Drug and Device Firms (January 2004) describes two types of drug labeling: FDA-approved labeling, and promotional labeling. An example of FDA-approved labeling is the Professional Package Insert (PPI). Promotional labeling generally includes all other prescription drug labeling e.g. a Dear Healthcare Professional Letter. With the exception of Consumer Medical Information, this paper describes only FDA-approved labeling.
In addition to the PPI, FDA approved labeling includes FDA approved patient labeling and Medication Guides (though subsumed into PPIs) and in the case of nonprescription products, Drug Facts Labeling. Another entity to be described is consumer medication information (CMI). See Table 2 for the basis of each.
[wpsm_comparison_table id=”15″ class=”customTable autoWidth textLeft”]
Professional Labeling/Professional Package Insert (PPI)
The PPI is “the official description of a drug product, which includes indication (what the drug is used for); who should take it; adverse events (side effects); instructions for use in pregnant women, children and other populations, and safety information for the patient.” PPIs are considered the primary means of communicating information about drug products and serve as the basis for many other types of prescriber and patient materials including communications with healthcare providers (e.g. promotional labeling), pharmacists, and patients. It is important to note that it is the duty of the manufacturer to continually amend their package inserts, and that oral communications, advertising and promotional labeling that are not consistent with the PPI have the potential of rendering a drug misbranded.
FDA Approved Patient Labeling
FDA approved patient labeling (aka Patient Package Insert) should not be confused with patient counseling information, which is information for prescribers to share with patients. Nor should Medication Guides be considered the only type of approved patient labeling. Medication Guides only accompany drugs that are subject to a Risk Evaluation Mitigation Strategy (REMS; see discussion below). However, each of these components, as applicable, will be located at section 17 of PLR formatted labeling. FDA approved patient labeling should not be confused with CMI (materials commonly distributed by the pharmacy as discussed below). FDA approved patient labeling is included in the professional labeling and is specifically targeted to the patient. Inclusion at section (17) allows the various forms of patient labeling to be more conveniently torn off and given to the patient and may also include instructions for use (IFU). Following are two illustrative examples:
- Cervarix® patient counseling information contains no medication guide but does include patient labeling: (17) PATIENT COUNSELING INFORMATION: “Advise the patient to read the FDA-approved patient labeling (Patient Information). Patient labeling is provided as a tear-off leaflet at the end of this Full Prescribing Information”.
- Duragesic® does contain a medication guide but also points the patient to an IFU: (17) PATIENT COUNSELING INFORMATION: “Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use)”.
As if this were not confusing enough, the CFR at subsection (c)(18) describes PLR labeling section 17. Emphasis added. This is illustrated in Table 3. Remember this anytime you review any labeling section in 21 CFR 201.57:
[wpsm_comparison_table id=”16″ class=”customTable autoWidth textLeft VATop”]
To understand what distinguishes a Medication Guide from other FDA approved patient labeling, one must understand FDA’s Risk Evaluation and Mitigation Strategies, or “REMS”. REMS are “required risk management plans that use risk minimization strategies beyond the professional labeling to ensure that the benefits of certain prescription drugs outweigh their risks”. The REMS program came about as a result of a new law passed in 2007 known as the Food and Drug Administration Amendments Act (aka FDAAA). FDAAA gave FDA many new authorities and responsibilities to enhance drug safety.
One of the components of a REMS that might be assigned by FDA is the Medication Guide. Medication Guides contain “prescription drug information for certain medications that pose a serious and significant public health concern, developed by the manufacturer, approved by FDA, and required to be distributed to consumers each time the medication is dispensed”.
Any drug that requires a new Medication Guide is considered to have a REMS. However, because many Medication Guides predate FDAAA/REMS, there are drugs with Medication Guides that are not part of the REMS program.
Consumer Medication Information (CMI)
You have probably noticed something that resembles drug product labeling stapled to the bag containing prescriptions dispensed by your pharmacist. This is CMI aka PMI (Patient Medication Information), which is developed by third party vendors such as First Data bank or Wolters Kluwer Health. CMI is not part of FDA-approved labeling, nor is it approved by FDA. The history of CMI is fascinating and the effectiveness questionable. The Guidance describes the history in fairly minute detail and FDA’s Consumer Medication Information: Expert and Consumer Evaluation of Consumer Medication Information describes various effectiveness metrics. The purpose of such labeling has been to provide consumers with easy access to information regarding their prescription medications and is intended to be “clear, current, accurate, actionable, and accessible”.
Drugs Facts Labeling
The “Drug Facts Rule” was finalized on March 17, 1999, standardized format and content requirements for nonprescription labeling, and is codified at 21 CFR 201.66. When the rule was finalized, it was summarized as follows:
SUMMARY: “The Food and Drug Administration (FDA) is issuing a final rule establishing a standardized format and standardized content requirements for the labeling of over-the-counter (OTC) drug products. This final rule is intended to assist consumers in reading and understanding OTC drug product labeling so that consumers may use these products safely and effectively. This final rule will require all OTC drug products to carry the new, easy-to-read format and the revised content requirements within prescribed implementation periods.”
Drug Facts Labels are those easily recognizable labels on most of the nonprescription drug products on pharmacy shelves. Drug Facts labeling is required whether the drug is marketed through the monograph system or via an approved NDA. It should be noted that there are certain nonprescription drugs that also have professional labeling.
If you have questions or concerns regarding your drug product’s labeling, feel free to click here to contact us.
Charles Jaap is Vice-President of Operations and Business Development for PDG, a global pharmaceutical and medical device consultant with extensive experience in the strategic development of drug products and medical devices. Please feel free to contact us for more information.
The opinions and statements in this paper are solely those of Charles Jaap and do not necessarily reflect those of PDG.